Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + paclitaxel + vinorelbine
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of epirubicin, paclitaxel, and vinorelbine. This combination has been studied primarily for the treatment of breast cancer, particularly in the neoadjuvant setting for stage II/III operable breast cancer. The regimen typically follows a specific schedule with vinorelbine and epirubicin given on days 1 and 8, followed by paclitaxel on day 9, with G-CSF support on days 10-20 of a 21-day cycle.
- Other names
- VEP protocolVEP regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + paclitaxel + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + paclitaxel + vinorelbine.